DNA methylation is an epigenetic mechanism for gene silencing engaged by DNA methyltransferase (Dnmt)-catalyzed methyl group transfer to cytosine residues in gene-regulatory regions. It is unknown whether aberrant DNA methylation can cause neurodegeneration. We tested the hypothesis that Dnmts can mediate neuronal cell death. Enforced expression of Dnmt3a induced degeneration of cultured NSC34 cells. During apoptosis of NSC34 cells induced by camptothecin, levels of Dnmt1 and Dnmt3a increased fivefold and twofold, respectively, and 5-methylcytosine accumulated in nuclei. Truncation mutation of the Dnmt3a catalytic domain and Dnmt3a RNAi blocked apoptosis of cultured neurons. Inhibition of Dnmt catalytic activity with RG108 and procainamide protected cultured neurons from excessive DNA methylation and apoptosis. In vivo, Dnmt1 and Dnmt3a are expressed differentially during mouse brain and spinal cord maturation and in adulthood when Dnmt3a is abundant in synapses and mitochondria. Dnmt1 and Dnmt3a are expressed in motor neurons of adult mouse spinal cord, and, during their apoptosis induced by sciatic nerve avulsion, nuclear and cytoplasmic 5-methylcytosine immunoreactivity, Dnmt3a protein levels and Dnmt enzyme activity increased preapoptotically. Inhibition of Dnmts with RG108 blocked completely the increase in 5-methycytosine and the apoptosis of motor neurons in mice. In human amyotrophic lateral sclerosis (ALS), motor neurons showed changes in Dnmt1, Dnmt3a, and 5-methylcytosine similar to experimental models. Thus, motor neurons can engage epigenetic mechanisms to drive apoptosis, involving Dnmt upregulation and increased DNA methylation. These cellular mechanisms could be relevant to human ALS pathobiology and disease treatment.
Introduction
DNA methylation is an epigenetic process whereby a DNA methyltransferase (Dnmt) catalyzes the covalent transfer of a methyl group from S-adenosyl-methionine to the 5Ј carbon position of a substrate cytosine residue (Cheng, 1995; Pradhan et al., 1999; Bestor, 2000; Szyf, 2005) . This reaction is part of a complex mechanism for gene regulation. DNA methylation changes protein-DNA interactions that lead to alterations in chromatin structure and rate of transcription (Jones and Takai, 2001) . Generally, when DNA methylation is involved in gene silencing, cytosine methylation occurs in cytosine-phosphate-guanine (CpG) dinucleotides within the 5Ј regulatory regions of genes (Bird, 2002; Brenner and Fuks, 2006) . CpG-rich areas are referred to as CpG islands (Bird, 2002; Brenner and Fuks, 2006 ) and have been defined as a region of 200 bp where guanine-cytosines make up Ͼ50% of the region and CpGs are Ͼ60% of the observed/expected ratio within that region (Gardiner-Garden and Frommer, 1987) . There are ϳ3 ϫ 10 7 residues of 5-methylcytosine in the mammalian genome, and 40% of genes contain CpG islands in their promoters (Bestor, 2000; Fatemi et al., 2005) . CpG-rich areas in promoters are one of the initiation sites where transcription factors bind to the DNA allowing transcription of the corresponding gene. When these regulatory regions are methylated, transcription factors are unable to bind DNA, thus inhibiting gene transcription (Kimura and Shiota, 2003) . The transcriptional repression involves the methylated cytosines operating in a stable multiprotein complex of corepressors to modify chromatin structure and inhibit transcription (Razin, 1998; Curradi et al., 2002) . Several isoforms of Dnmts have been cloned. Dnmt1 is the most abundant isoform in proliferating cells, displays a preference for hemimethylated substrates, and is targeted to replication forks, acting to maintain methylation patterns during cell replication (Robertson, 2001) . Dnmt2 transfers methyl groups to RNA, not DNA (Schaefer and Lyko, 2010) . Dnmt3a and Dnmt3b function as de novo methyltransferases because they methylate hemimethylated DNA and also completely unmethylated DNA Xie et al., 1999) . Dnmt3L functions as an essential regulatory cofactor (Jia et al., 2007) . Dnmts are essential for proper nervous system development (Martinowich et al., 2003) and are present in adult brain and in neurons (Feng et al., 2005 (Feng et al., , 2010 . Aberrant methylation of DNA has been implicated in neurological disorders, including Rett syndrome (Kondo et al., 2000) ; mutations in the Dnmt3b gene cause immunodeficiency centromeric region instability and facial anomalies syndrome . The functions of Dnmts in postmitotic neu-NSC34 cell cultures were differentiated over 12-20 d. The sustained culturing and differentiation was done to determine whether NSC34 cells could achieve large, polygonal motor neuron-like somatodendritic morphologies. NSC34 cells at 5 d in vitro (DIV5) were compared with NSC34 cells cultured for [14] [15] [16] [17] [18] [19] [20] . To assess morphological differentiation in living cells, transfection with Vitality-GFP vector (Stratagene) was done. Differentiation was also specified by immunophenotyping for neurofilament, microtubule-associated protein 2 (MAP2), and synaptophysin (Chang and Martin, 2011) . For immunocytochemistry, DIV5 and DIV14 -20 NSC34 cultures grown on chamber slides were fixed for 20 min in 4% paraformaldehyde in 4% sucrose-PBS. Cells were immunostained with a mouse monoclonal antibody to neurofilament-H (SMI32; Sternberger Monoclonals), a mouse monoclonal antibody to MAP2 (Roche), and a rabbit polyclonal antibody to synaptophysin (Dako). Alexa-488-and Alexa-594-conjugated secondary antibodies were used. Cells were imaged with a Meta confocal microscope (Carl Zeiss Microimaging), and pictures were captured using ZEN 2007 Light Edition software (Carl Zeiss Microimaging) . The nuclear sizes of NSC34 cells, stained with Hoechst 33258, were quantified using ImageJ software (NIH).
Caspase-3 activity assay. NSC34 neurons were disrupted in cell lysis buffer and microcentrifuged (10,000 ϫ g), and supernatants were evaluated for the activity of caspases that recognize the Asp-Glu-Val-Asp (DEVD) sequence using a colorimetric assay kit based on the detection of p-nitroaniline after cleavage from DEVD (Millipore Corporation). Absorbance was read spectrophotometrically at 405 nm. Human recombinant active caspase-3 (Millipore Corporation) was used as a positive control. Treatment of samples with caspase-3 inhibitor (Ac-DEVD-CHO) was the negative control.
siRNA knockdown of Dnmt1 and Dnmt3a in cell culture. NSC34 cells were transiently transfected using Dharmacon siGENOME SMART Pool predesigned siRNAs (Thermo Fisher Scientific). Transfections using siRNAs were designed to target independently Dnmt1 and Dnmt3a. siRNA targeting ␤-amyloid cleaving enzyme-1 (BACE1) was used as an independent target negative control. A total of 5 nmol per well of the siGENOME was used with 4 l of DharmaFECT-4 lipid reagent. The NSC34 cells were transfected for 4 h before removing the transfection medium and replacing it with cell culture medium. The cells were maintained for an additional 48 h before harvesting of total cell lysates for Western blotting.
Neuronal cell culture model of apoptosis using camptothecin. To induce apoptosis in NSC34 cells, they were treated with the DNA topoisomerase-I inhibitor camptothecin (CPT) (Sigma). CPT induces DNA single-strand breaks and apoptosis robustly in mouse cortical neurons as described previously (Martin et al., 2009a) . Because our previous experiments have shown that the molecular regulation of DNA damageinduced apoptosis can be different in cortical neurons at different stages of differentiation and synaptic maturation, we studied Dnmt-related changes during CPT-induced apoptosis in NSC34 cells at different states of in vitro maturation at DIV5 and DIV20. CPT was dissolved in distilled water supplemented with sodium hydroxide as described previously (Lesuisse and Martin, 2002) to give a final stock concentration of 10 mM. NSC34 cells were treated by replacing the culture medium with fresh medium containing 10 M CPT or vehicle at DIV14 -20. Cell lysates were harvested from vehicle and CPT-treated NSC34 cells exposed for 4, 8, 16 , and 24 h.
Dnmt enzyme activity assay. Total Dnmt enzymatic activity (maintenance and de novo) was measured in NSC34 cells and spinal cord extracts using a biochemical assay (Epigentek). In this ELISA-like assay, Dnmts transfer a methyl group to a cytosine-rich substrate DNA that is then detected by 5-methycytosine (5-mC) antibody. The enzymatic activity was determined by colorimetric measurement at 450 nm. Validation tests for this assay included pharmacologic inhibition of Dnmts with N-phthalyl-L-tryptophan (RG108) and procainamide, as well as genetic knockdown of Dnmts with siRNA.
Dnmt inhibition in CPT-treated NSC34 cells. To determine whether Dnmt inhibition exerts neuroprotective consequences, established small molecule inhibitors of Dnmts were used. The inhibitors were RG108 and procainamide hydrochloride. Both drugs are cell permeable and direct inhibitors of Dnmts (Brueckner et al., 2005; Lee et al., 2005) . RG108 (Calbiochem) was solubilized in DMSO at a stock concentration of 10 mM. Procainamide (Sigma) was dissolved in distilled DNase/RNase-free H 2 0 at a stock concentration of 1 M. NSC34 cells were treated with highglucose DMEM containing either 20 M RG108 or 500 M procainamide for 2.5 h. The medium containing RG108 and procainamide was removed and replaced with culture medium (50% DMEM, 50% optimem) containing 10 M CPT for 24 h. The cells were fixed and stained with Hoechst 33258 to assess apoptotic cell number or they were used to prepare cell lysates for Western blotting.
After Dnmt knockdown by siRNAs was validated by Western blotting, Dnmt RNAi was assessed in a neuroprotection experimental design. NSC34 cells were transfected with Dnmt3a siRNA 24 h before treatment with 10 M CPT. NSC34 cell lysates were harvested for Western blotting 24 h later.
Dnmt protein expression in developing and adult mouse CNS. The temporal profiles of Dnmt1 and Dnmt3a protein expression were determined in immature and mature mouse brain and spinal cord. Wild-type C57BL/6J mice were used. Brains and spinal cords were harvested from mouse pups at postnatal day 0 (P0) (day of birth), P5, P10, P15, P20, P25, P30, and from 6-to 8-week-old adults. The mice were deeply anesthetized by hypothermia or overdosed with sodium pentobarbital and decapitated, and the brain and spinal cord were removed quickly and placed in ice-cold HBSS. Whole brains and spinal cords were used to prepare nuclear protein, soluble protein, and mitochondrial-enriched membrane protein fractions by subcellular fractionation using a confirmed protocol (Martin et al., 2003) and further validation by Western blotting for tissue fraction-specific proteins. For each time point, two to four mice were harvested. Both genders were used. With adult mouse brain and spinal cord, a Nycodenz gradient procedure also was used to isolate pure mitochondria for Western blot detection of Dnmt1 and Dnmt3a. The tissue was placed in homogenization buffer at a 1:5 (w/v) ratio, sonicated, and centrifuged at 1300 ϫ g for 10 min. The pellet was resuspended in 0.5 volume of homogenization buffer and centrifuged at 1300 ϫ g for 10 min. The supernatant was centrifuged at 17,000 ϫ g for 15 min in an ultracentrifuge with a swinging bucket rotor. The supernatant was then removed, and the pellet was resuspended in 25% Nycodenz. The resuspended pellet was layered onto 2 ml of 30% Nycodenz, and 2 ml of 23% Nycodenz was layered on top of the 25% Nycodenz. The Nycodenz gradient was centrifuged at 52,000 ϫ g for 1.5 h in an ultracentrifuge, and the pure mitochondria fraction was removed from between the 25 and 30% layer interface. The subcellular fractionation was confirmed by Western blotting with monoclonal antibodies against nuclear and mitochondrial proteins. The nuclear compartment was tracked by the presence of NeuN, and the mitochondrial compartment was tracked by the presence of complex V.
Mouse model of motor neuron apoptosis. A unilateral sciatic nerve avulsion (SNA) served as the model for inducing apoptosis in motor neurons in vivo to determine whether Dnmts function in this cell death. The validation and reproducibility of this motor neuron degeneration model in mouse has been described previously (Martin and Liu, 2002; Martin et al., 2005) . SNA lesions were done on adult wild-type male C57BL/6J mice and on B6.Cg-Tg (Hlxb9-gfp)1Tmj/j transgenic mice expressing EGFP driven by the mouse Hlxb9 (Hb9) promoter (Wichterle et al., 2002) originally obtained from The Jackson Laboratory. Adult Hb9-eGFP mice have subsets of spinal motor neurons highly expressing EGFP (Chang and Martin, 2011; Martin, 2011) . SNA mice were used for biochemical and histological experiments. A cohort of wild-type mice with SNA lesions was killed at 1, 2, 3, 4, 5, or 6 d later (n ϭ 4 mice per time) by anesthesia overdose and decapitation for harvesting fresh spinal cord samples. Samples of lumbar spinal cord ventral horn columns (ipsilateral and contralateral) were collected by careful microdissection under a microsurgical stereomicroscope as described previously (Martin et al., 2005) . Samples from the different mice were pooled and fractionated into nuclear-enriched, mitochondrial-enriched, and soluble compartments as described previously (Martin et al., 2003) . A cohort of Hb9-eGFP mice with SNA lesions was killed at 1, 2, 3, 4, 5, 6, 7, 10, and 14 d later (n ϭ 4 mice per time) by anesthesia overdose and perfusion fixation with 4% paraformaldehyde for immunohistochemical studies of Dnmts and 5-methylcytosine in lumbar spinal cord. A cohort of wild-type mice was implanted with intracerebroventricular (ICV) cannulas and received the SNA. These mice were ICV treated with 5 or 10 g of RG108 (in 2 l of sterile saline) or with vehicle on day 0 (day of lesion) and on every other postlesion day over 3 weeks and were killed at postlesion day 21. Another group of RG108-or saline-treated mice was killed at 3, 4, and 7 d after lesion. The mice were killed by anesthesia overdose and perfusion fixation in 4% paraformaldehyde for spinal cord histology, immunohistochemistry, and neuroprotection analysis. The institutional Animal Care and Use Committee approved the animal protocols.
Western blotting. The protein concentrations of cell lysates or brain and spinal cord extracts and subcellular fractions were determined using the Bio-Rad protein assay (Pierce Chemical). Proteins from cultured cell lysates and tissue extracts of brain and spinal cord fractions were subjected to SDS-PAGE (4 -12%) and transferred to nitrocellulose membrane by electroelution as described previously (Martin, 1999) . The reliability of sample loading and electroblotting in each blot was evaluated by staining nitrocellulose membranes with Ponceau S before immunoblotting. If transfer was not uniform, blots were discarded and gels were run again. Blots were blocked with 2.5% nonfat dry milk with 0.1% Tween 20 in 50 mM Tris-buffered saline, pH 7.4, and incubated overnight at 4°C with an antibody. The primary antibodies used were mouse monoclonal anti-Dnmt1 (clone 60B1220.1; Alexis Laboratories), rabbit polyclonal anti-Dnmt1 (1:500; Bethyl Laboratories), mouse monoclonal anti-Dnmt3A (clone 64B1446; Alexis Laboratories), rabbit polyclonal anti-Dnmt3a (1:1000; Abgent), mouse monoclonal anti-phospho-p53 (1:10,000; Cell Signaling Technology or R&D Systems), rabbit polyclonal anti-cleaved caspase-3, (1:500; Cell Signaling Technology), mouse monoclonal anti-NeuN (1:2000; Millipore Corporation), mouse monoclonal anti-complex V (1:10,000; Invitrogen), mouse monoclonal anti-MAP2 (Roche Diagnostics), or mouse monoclonal anti-␣-actin (1: 10,000; Millipore Corporation). The antibodies were used at concentrations for visualizing protein immunoreactivity within the linear range (Lok and Martin, 2002) . After the primary antibody incubation, blots were washed and incubated with horseradish peroxidase-conjugated secondary antibody (0.2 g/ml), developed with enhanced chemiluminescence (Pierce Chemical), and exposed to x-ray film or imaged using a ChemiDoc XRS Gel documentation system. Western blots were analyzed quantitatively by densitometry using Quantity One analysis software (Bio-Rad). Western blots were done in triplicate or greater, and the fold change was calculated by dividing the optical density of each time point by the loading control optical density. Protein loading controls were blots probed for ␣-actin, MAP2, or nitrocellulose membranes stained with Ponceau S. In some instances, the reprobing failed to give a reliable signal and the Ponceau S-stained membrane was used for normalization. In developmental, subcellular fraction, and lesion experiments, standard housekeeping proteins are unsuitable for protein loading because of developmental changes in cytoskeletal proteins, normal differences in cellular compartmentalization, and injury-induced changes in cytoskeletal proteins, respectively; thus, Ponceau S was used for normalization. Other studies have recognized some of the limitations of housekeeping proteins for references in Western blotting (Ferguson et al., 2005; Dittmer and Dittmer, 2006; Liu and Xu, 2006) .
Immunohistochemistry. After perfusion fixation, Hb9-eGFP and wildtype mouse spinal cords were removed from the vertebral column by dorsal laminectomy and cryoprotected in phosphate-buffered 20% glycerol. Dnmt1, Dnmt3a, and 5-methylcytosine were localized in lumbar spinal cord by a peroxidase-anti-peroxidase detection method using diaminobenzidine (DAB) as chromogen. The primary antibodies used (determined as appropriate for use in immunohistochemistry when Western blotting showed detection of monospecific bands or by nucleic acid digestion) were mouse monoclonal anti-Dnmt1 (1:1000, Alexis Laboratories), rabbit polyclonal anti-Dnmt3a (1:500; Abgent), or mouse monoclonal anti-5-methylcytosine (clone 162 33 D3, 1:1000; Calbiochem). After counterstaining with cresyl violet, the sections were viewed by bright-field microscopy and imaged using a Dxm 1200 digital camera (Nikon) and ACT-1 software.
Hb9-eGFP and wild-type mouse spinal cord sections were also used to detect immunofluorescence of Dnmt1 and Dnmt3a specifically in motor neurons using Alexa-594-conjugated secondary antibody (Invitrogen).
Immunofluorescence was also used for colocalization of Dnmt3a with the mitochondrial marker cyclophilin D (Martin et al., 2009b) , Dnmt3a with the synaptic marker synaptophysin (Calhoun et al., 1996) , and 5-methylcytosine with the mitochondrial marker superoxide dismutase-2 (SOD2) (Martin et al., 2007; Chang and Martin, 2009 ) using combinations of primary antibodies generated in different species. AlexaFluor-488-and AlexaFluor-594-conjugated secondary antibodies (Invitrogen) were used for detection. After counterstaining with DAPI and coverslipping, the sections were viewed using a LSM 510 confocal microscope (Carl Zeiss Microimaging).
Motor neuron measurements. Mouse lumbar spinal cord enlargements were dissected under a surgical microscope, and L4, L5, L6, and S1 segments were cryoprotected in 20% glycerol-PBS and frozen under pulverized dry ice. Transverse serial symmetrical sections (40 m) through the spinal cord were cut using a sliding microtome and stored individually in 96-well plates. Sections were selected with a random start and systematically sampled (every ninth section) to generate a subsample of sections from each spinal cord that were mounted on glass slides and stained with cresyl violet for neuronal counting. Neuronal counts in the ipsilateral and contralateral ventral horns were made at 1000ϫ magnification using the stereological optical dissector method as described previously (Calhoun et al., 1996; Martin et al., 1999) . Motor neurons without apoptotic structural changes were counted using strict morphological criteria. These criteria included a round, open, pale nucleus (not condensed and darkly stained); globular Nissl staining of the cytoplasm; and a diameter of ϳ30 -45 m. With these criteria, astrocytes, oligodendrocytes, and microglia were excluded from the counts. Nissl-stained sections of lumbar spinal cord sections were used to determine motor neuron cell body volume. Motor neurons were observed at 1000ϫ magnification, and with a calibrated ocular micrometer, the major axis diameter (including the largest proximal dendrite) and the minor axis diameter were measured for 25-50 different motor neurons in each mouse. Cell body volume was calculated from the equation V ϭ (/6)ab 2 , where a is the diameter of the major axis and b is the diameter of the minor axis (Wong and Martin, 2010) . Neuronal counts and volumes in the contralateral ventral horn always served as controls for the ipsilateral ventral horn. Neuronal counts and volumes were used to determine group means and variances, and comparisons among groups were analyzed using a one-way ANOVA and a Newman-Keuls post hoc test.
Human CNS tissues. Postmortem human brain and spinal cord samples were derived from the Human Brain Resource Center at the Department of Pathology, Johns Hopkins University School of Medicine. Control (n ϭ 12) and sporadic amyotrophic lateral sclerosis (ALS) cases (n ϭ 12) were matched for age and postmortem delay (Martin, 1999 (Martin, , 2000 Shaikh and Martin, 2002) . Snap-frozen samples of motor cortex and spinal cord were used for Western blotting for Dnmt1 and Dnmt3a after subcellular fractionation as described previously (Martin, 2000) . Nuclear and mitochondrial enrichment of human CNS tissue fractions was confirmed by detection of NeuN and CyPD, respectively. Paraffinembedded CNS samples were used for immunohistochemical localization of Dnmt1, Dnmt3a, and 5-methylcytosine using DAB as the chromogen and counterstaining with cresyl violet.
Results

Dnmt protein expression in neural cell lines
We screened several commercial antibodies to Dnmt isoforms for reliability in detecting monospecifically Dnmt1 and Dnmt3a in neural and non-neural cell lines (Fig. 1) . For positive controls, mouse Dnmt1 and Dnmt3a genes were overexpressed in different cell lines by transient transfection, and cell lysates were used for Western blotting; also, purified E. coli-derived recombinant human Dnmt1 and Dnm3a (R&D Systems) were loaded onto gels. Negative control experiments were probing blots with a primary antibody preadsorbed against recombinant Dnmt1 and Dnmt3a protein and with a secondary antibody alone. Figure 1 A shows the relative endogenous levels of putative Dnmt1 and Dnmt3a in cultured HEK293 cells, NSC34 cells, astrocytes, and microglia. The immunoreactive band identified as Dnmt1 had a molecular mass of ϳ190 kDa, consistent with its predicted size (Inano et al., (NSC34), mouse brain astrocytes, and mouse brain microglia. B, Negative control antibody preadsorption assay. NSC34 cells were harvested and lysed, and the protein lysates were used for the preadsorption test or nonpreadsorbed controls. Antibody to Dnmt1 or Dnmt3a diluted to 1:1000 (w/v) was incubated with Dnmt1 or Dnmt3a recombinant protein (1:10 and 1:100, ratios of antibody to recombinant protein). After incubation to form the antibody/protein complex, the samples were centrifuged, and the supernatant was collected and used to probe Western blot (20 g of protein). Ponceau S staining was used to verify protein loading in each lane. C, Cultured HEK and mouse neural cells were transfected with Dnmt1 or Dnmt3a vectors to enforce expression or were mock transfected as a control. The transfected cells were harvested and lysed, and proteins were used for Western blotting. Ponceau S-stained membrane shows protein loading. D, E, RNAi knockdown of Dnmts. NSC34 cells were transiently transfected using siRNAs targeting independently Dnmt1 and Dnmt3a. The cultured cells were harvested 48 h later. siRNA-Dnmt cell lysates (20 g of total protein) were used for immunoblotting for Dnmt1 and Dnmt3a. The graph displays the Dnmt1 and Dnmt3a immunoreactivity levels as percentage of control optical density (OD; mean Ϯ SD) after siRNA-Dnmt1 and siRNA-Dnmt3a in NSC34 cells (asterisks indicate significant difference from control; see Results). Independent experiments were done in triplicate. F, Knockdown of Dnmt enzyme activity with RNAi. NSC34 whole-cell lysates after Dnmt1-and Dnmt3a-siRNA construct transfection were used to determine Dnmt enzyme activity biochemically. The total enzyme activities are represented as percentage of activity (mean Ϯ SD) compared with control mock-transfected NSC34 cells (asterisks indicate significant difference, p Ͻ 0.01). Independent experiments were done twice.
2000)
. The immunoreactive band identified as Dnmt3a had a molecular mass of ϳ100 kDa, consistent with its predicted size (Feng et al., 2005) . Endogenous levels of Dnmt1 were much higher in HEK293 cells compared with neural cell lines ( Fig. 1 A) , whereas the endogenous levels of Dnmt3a were similar among the different cell lines analyzed.
The proteins assumed to be Dnmt1 and Dnmt3a were verified as such by adsorption of a primary antibody with human recombinant Dnmt1 and Dnmt3a ( Fig. 1 B) , by transfection of cells with Dnmt1 and Dnmt3a expression plasmids (Fig. 1C) , and by RNAi knockdown (Fig. 1 D) . Enforced expression of Dnmt1 and Dnmt3a above endogenous (mocktransfected) levels was demonstrated in HEK293 cells, NSC34 cells, astrocytes, and microglia (Fig. 1C) . Transfection of siRNAs designed to target Dnmt1 and Dnmt3a independently confirmed antibody specificity by robustly reducing the proteins levels of Dnmt1 and Dnmt3a ( Fig. 1 D, E ), but the knockdown was not completely isoform specific. The Western blot analysis for siRNA-Dnmt1 showed a significant ( p ϭ 0.005) decrease in Dnmt1 immunoreactivity ( Fig. 1 D, E ). Dnmt3a immunoreactivity was also significantly ( p ϭ 0.04) decreased by siRNA-Dnmt1 ( Fig. 1 D, E) . Western blot analysis of siRNA-Dnmt3a cells showed a highly significant ( p ϭ 0.0002) decrease in Dnmt3a immunoreactivity in NSC34 cells and also a significant ( p ϭ 0.001) decrease in Dnmt1 immunoreactivity ( Fig. 1 D, 
E).
RNAi knockdown of Dnmt1 and Dnmt3A was also successful in causing a significant reduction in biochemical enzyme activity for Dnmt (Fig. 1 F) . The siRNA-Dnmt1 had a 28% decrease in activity in the NSC34 cells compared with control cells, and the siRNA-Dnmt3a had a 26% decrease in activity ( Fig. 1 F) . These results demonstrate our capacity to accurately assess Dnmts at protein and enzyme activity levels.
Overexpression of Dnmt3a induces neurodegeneration
In the course of cell transfection experiments for antibody validation, we observed serendipitously that enforced expression of Dnmt3a, but not Dnmt1, had cytopathic effects. We then engineered mammalian expression constructs for Dnmt1-and Dnmt3a-GFP fusion proteins. NSC34 cells were transfected with the Dnmt-GFP constructs or a GFP expression plasmid as a control. Control cells expressing GFP showed a diffuse expression pattern throughout the entire cell ( Fig. 2A) . In Dnmt1-GFP transfectants, Dnmt1 was localized entirely to the cell nucleus and seen as discrete small foci (Fig. 2B ). NSC34 cells transfected with Dnmt3a-GFP construct exhibited a markedly different pattern of localization from those transfected with Dnmt1. Dnmt3a-GFP was primarily cytoplasmic and was seen as discrete (2 g) show that Dnmt1 is localized selectively in the nucleus with a striking punctate labeling pattern. C, Cells transfected with plasmid pORF9 Dnmt3a-GFP (2 g) exhibit nuclear and marked punctate cytoplasmic localizations (open arrows) of Dnmt3a and also show nuclear condensation and fragmentation (hatched arrows). Scale bar, 7 m. D, Graph showing measurements of nuclear diameters (mean Ϯ SD; asterisk indicates significant difference, p Ͻ 0.05) in transfected cells (n ϭ 20 cells per group). E, Total Dnmt enzyme activity (mean Ϯ SD of absorbance) in NSC34 cell lysates after Dnmt1 and Dnmt3a transfection. Asterisks indicate significant difference ( p Ͻ 0.05) compared with control. F, Caspase-3 enzyme activity in NSC34 cells overexpressing Dmnt1 and Dnmt3a at 24 h after plasmid or mock transfection. Asterisk indicates significant difference ( p Ͻ 0.05) compared with control. G, Western blot determination of cleaved capsase-3 formation in NSC34 cells overexpressing Dmnt1 and Dnmt3a at 24 h after plasmid or mock transfection. MAP2 immunoreactivity was used as a protein loading control. punctate structures (Fig. 2C) . Moreover, the overexpression of Dnmt3a-GFP caused the neurons to degenerate (Fig. 2C ). This degeneration was characterized by nuclear condensation as well as cellular fragmentation and blebbing that occurred over 48 -72 h. Dnmt3a overexpression caused a 2.1-fold decrease in nuclear size, but enforced expression of Dnmt1 did not cause nuclear shrinkage or cell fragmentation (Fig. 2D) . To confirm that the overexpressed Dnmts were catalytically active forms of enzyme, we measured biochemically total Dnmt activity in transfected NSC34 cell lysates. Total Dnmt enzyme activity was increased 2-and 1.6-fold in the Dnmt1-and Dnmt3a-transfected cells, respectively, compared with the mock-transfected controls (Fig.  2E ). Because the neurodegeneration induced by enforced expression of Dnmt3a had some nuclear morphology features reminiscent of apoptosis, we assayed for caspase-3. NSC34 cells overexpressing Dnmt3a for 24 h, but not Dnmt1, showed significance increases in caspase-3 enzyme activity ( Fig. 2F) and formation of the active small subunit as seen by Western blotting (Fig. 2G ).
Mutant catalytically inactive Dnmt3a is impotent at inducing cell degeneration
We engineered an expression construct containing the Dnmt3a gene with a deletion in the DNA sequence encompassing Ͼ93% of the catalytic domain of the encoded protein (Fig. 3A) to determine whether the cell degeneration is related specifically to the methytransferase activity of Dnmt3a. NSC34 cells transfected with the Dnmt3a-GFP deletion plasmid (Dnmt3a⌬-GFP) survived, differentiated neuron-like cells, and remained viable for beyond 16 d after transfection without evidence of nuclear condensation or cell fragmentation (Fig. 3B,C) . Moreover, NSC34 cells transfected with mutant Dnmt3a did not show evidence for caspase-3 activation compared with cells transfected with active Dnmt3a, which showed robust accumulation of active caspase-3 subunit at 24 h after transfection (Fig. 3 F, G) .
Dnmt3a localizes to mitochondria in NSC34 cells
The survival of neurons overexpressing Dnmt3a⌬-GFP allowed for determination of the subcellular localization of Dnmt3a without the confounding effects of rapid degeneration. Dnmt3a⌬-GFP was observed within the nucleus where it was seen as small foci distributed within the nuclear matrix (Fig. 3 B, C) . Dnmt3a⌬-GFP was prominent in the cytoplasm where it was seen as punctuate structures resembling mitochondria in the cell body and processes (Fig. 3C) . We used to transiently cotransfect NSC34 cells our Dnmt3a-GFP deletion plasmid and a plasmid expressing DsRed monomer fluorescent protein with a mitochondrial localization (SU9) sequence to determine whether Dnmt3a localizes to mitochondria. Cytoplasmic Dnmt3a showed considerable localization to mitochondria in NSC34 cells (Fig. 3C-E) .
Motor neuron-like cell culture model of apoptosis Most reports using NSC34 cells show scant or no evidence for their differentiation into cells resembling neurons (Tovar-yRomo et al., 2009), although NSC34 cells are frequently referred to in the literature as a motor neuron-like cell model (Cashman et al., 1992) ; therefore, we evaluated the ability of NSC34 cells to differentiate into motor neuron-like cells. We compared NSC34 cells cultured for 5 d (DIV5) and cells cultured for [14] [15] [16] [17] [18] [19] [20] . During this differentiation process, there was an underlying cell-survival selection process as witnessed by an ϳ50% reduction cell number (Fig. 4A) . Morphological differentiation was determined by transfection with the GFP expression plasmid to visualize the entire cell and by immunostaining fixed NSC34 cells with dendritic and synaptic markers. DIV5 NSC34 cells were predominantly immature, and undifferentiated cells were seen as small (Ͻ10 m) in diameter and mostly round or bipolar in shape (Fig.  4 A) . In contrast, many DIV20 NSC34 cells were large (Ͼ20 m in diameter) and multipolar (Fig. 4 A) as shown by GFP expression and SMI-32 monoclonal antibody (Fig. 4 A) , which recognizes a nonphosphorylated epitope of the neurofilament protein SMI-32 within neurons and is used to identify motor neurons in culture (Chang and Martin, 2011) . Differentiated SMI-32-positive NSC34 cells had broad and long dendrites, with some spanning Ͼ50 m (Fig. 4 A) , and were choline acetyltransferase positive (data not shown). Differentiated NSC34 cells also possessed elaborate dendritic arbors seen by MAP2 immunostaining that were decorated by numerous presynaptic terminals detected by synaptophysin immunostaining (Fig. 4B) . Synaptophysin-positive presynaptic boutons were not detected in DIV5 NSC34 cell cultures (data not shown).
We wanted to study Dnmt expression patterns in a setting where immature, less differentiated, and differentiated NSC34 cells were induced to undergo apoptosis by treatment with the DNA-damaging agent CPT. CPT treatment of cultured mouse primary cortical neurons induces DNA single-strand break accumulation and robust p53-and caspase-dependent apoptosis (Martin et al., 2009a) . We determined that CPT treatment of NSC34 cells is a valid cell culture model of spinal cord neuron apoptosis. CPT induced robust apoptosis in NSC34 cells, as shown morphologically with Hoechst 33258-stained nuclei (Fig. 4C ) and biochemically by Western blot analysis showing increased levels of phospho-p53 (Fig. 4 D) and cleaved-caspase 3 (Fig. 4 E) .
Dnmt expression in apoptotic NSC34 cells
To identify possible relationships between Dnmts and apoptosis, we measured Dnmt protein expression patterns in NSC34 cells undergoing apoptosis. The cells were evaluated at DIV5 and DIV20, because cell death signaling mechanisms in mouse cortical neurons seem to vary depending on stage of maturation (Martin et al., 2009a) . The levels of Dnmt1and Dnmt3a in CPT-treated undifferentiated DIV5 NSC34 cells remained stable during the progression of apoptosis (Fig. 5 A, B) . In contrast, a significant threefold increase in Dnmt1 levels over control values occurred in differentiated DIV20 NSC34 cells ( p Ͻ 0.05) at 4 h after CPT treatment (Fig. 5C ). Subsequently, Dnmt1 levels were increased by 5.3-, 5.9-, and 5.4-fold at 8, 16, and 24 h, respectively, after CPT treatment (Fig. 5C ). Dntm3a levels were significantly increased ( p Ͻ 0.05) in DIV20 NSC34 cells, with 2.1-, 1.8-, 2.1-, and 2.1-fold increases being observed at 4, 8, 16 and 24 h, respectively, after CPT treatment (Fig. 5D ).
Dnmt drug inhibitors and RNAi protect against apoptosis and cytosine methylation in cultured neurons
To further assess the role of Dnmts in the direct mechanisms of neuronal apoptosis, we used drug inhibitors. RG108 is an isoform nonspecific DNA methyltransferase inhibitor (Brueckner et al., 2005) , whereas procainamide is a Dnmt1-specific inhibitor (Lee et al., 2005) . NSC34 cells were cultured and treated with either RG108 or procainamide before apoptosis induction by CPT. Both of the inhibitors decreased significantly the amount of apoptosis in differentiated NSC34 neurons (Fig. 5E ). Procainamide protected ϳ25% of the cells, whereas RG108 protected ϳ60% of the cells (Fig. 5E ). RNAi using Dnmt3a-siRNA, which mediates a more robust knockdown of Dnmt protein compared with Dnmt1-siRNA (Fig. 1D) , also decreased significantly the amount of NSC34 cell apoptosis induced by CPT (Fig. 5F ). siRNA knockdown of an independent target (BACE1) did not affect the levels of CPTinduced apoptosis (Fig. 5F ). The protection afforded by Dnmt3a-siRNA was confirmed at a biochemical level by Western blotting revealing that RG108 potently abolished the CPT-induced activation of p53 (Fig. 5G ) and caspase-3 cleavage (data no shown). Dnmt3a-siRNA also attenuated p53 phosphorylation in CPT-treated NSC34 cells (Fig. 5G) .
We examined the cellular localizations of Dnmt3a and a direct marker of DNA methylation (i.e., 5-methylcytosine) in CPTtreated NSC34 cells. By immunofluorescence, endogenous mouse Dnmt3a in control NSC34 cells is localized in the cytoplasm as a reticulum and discrete puncta (Fig. 6 A) , consistent with the patterns seen in human Dnmt3a-transfected NSC34 cells (Figs. 2C, 3C) , and basal levels appeared low in the nucleus (Fig.  6 A) . Similarly, 5-methylcytosine immunoreactivity is detectable, but low, in the nucleus of control NSC34 cells (Fig. 6C ). In contrast, CPT-treated NSC34 cells exhibited intense cytoplasmic im- Figure 5 . Dnmts can mediate DNA damage-induced apoptosis of differentiated neurons. A, B, Dnmt1 and Dnmt3a protein levels do not change significantly in DIV5 NSC34 cells exposed to 10 M CPT for 4 -24 h. Representative Western blots are shown along with membranes reprobed for actin to show protein loading. Immunoreactivity optical densities for DNMT1 and Dnmt3a were normalized to actin immunoreactivity. Values in graphs are mean Ϯ SEM of optical density units. C, D, Dnmt1 and Dnmt3a protein levels increase in DIV20 NSC34 cells exposed to 10 M CPT for 4 -24 h. Values in graphs are mean Ϯ SEM of optical density units. Asterisks denote a significant difference from control for Dnmt1 ( p Ͻ 0.01) and Dnmt3a ( p Ͻ 0.05). Representative Western blots are shown along with membranes reprobed for actin to show protein loading. E, Dnmt inhibitors protect against CPT-induced apoptosis. DIV20 NSC34 cells were treated with either 20 M RG108 or 0.5 mM procainamide for 2.5 h in optimem medium. The medium with inhibitors was removed, and the cells were treated with 10 M CPT for 24 h. The cells were fixed and stained with Hoechst 33258. The percentages of apoptotic cells were determined by counting total cell nuclei (n ϭ 1000 cells per condition) and the proportion of apoptotic nuclei. Values in graphs are mean Ϯ SEM. Double asterisks denote a significant difference from control for CPT ( p Ͻ 0.001). There is a significant difference from CPT-treated cells for RG108 ( ϩϩ p Ͻ 0.01) and procainamide ( ϩ p Ͻ 0.05). F, RNAi for Dnmt3a protects against CPT-induced apoptosis. DIV14 NSC34 cells were transfected with siRNA construct targeting Dnmt3a or BACE1 (as an independent target), and 24 h later, the cells were treated with 10 M CPT for 24 h. Cells were prepared as in E. Values in graphs are mean Ϯ SEM. ϩϩ Significant difference from control for CPT ( p Ͻ 0.001); ϩ Significant difference from CPT-treated cells for siRNAi cells ( p Ͻ 0.01). BACE1 knockdown (control siRNA ϩ CPT) did not protect. G, Western blot analysis of phospho-p53
Ser15 in NSC34 cells treated with RG108 (20 M) and Dnmt3a-siRNA and challenged with 10 M CPT for 24 h. RG108 dramatically blocked the CPT-induced activation of p53. Dnmt3a-siRNA attenuated the activation of p53 in CPT-treated cells. munoreactivity and definite nuclear staining for endogenous Dnmt3a (Fig. 6 B, D) and for 5-methylcytosine (Fig. 6 D) . 5-Methylcytosine immunoreactivity accumulated diffusely in the nuclear matrix and as prominent masses in the nucleus (Fig. 6 D) . RG108-treated cells markedly attenuated the immunostaining for Dnmt3a and 5-methylcytosine in CPT-treated NSC34 cells (Fig. 6 E) .
Endogenous Dnmt expression in developing mouse brain and spinal cord
To have a better understanding of DNA methylation enzymes in the intact CNS, we examined, by immunoblotting, the endogenous expression levels of Dnmt1 and Dnmt3a in the brain and spinal cord of mice. We determined whether Dnmt expression is developmentally regulated.
Western blotting of nuclear-enriched subcellular fractions from brain showed that there were no major changes in Dnmt1 protein levels in the developing mouse brain from the day of birth (P0) to P30 (Fig. 7A) . In contrast, Dnmt3a protein levels increased progressively in the developing mouse brain from P0 to P30 (Fig. 7A ). There were 2.76-and 3.38-fold increases from P0 to P10 and P0 to P15, respectively; the highest expression was reached at P15 (Fig. 7A) .
Nuclear-enriched fractions of spinal cord were studied at P0 -P20. Dnmt1 exhibited a twofold decrease from P5 to P10, and this decrease persisted throughout P15 and P20 (Fig. 7B) . Interestingly, Dnmt3a levels had an inverse relationship to Dnmt1 with a twofold increase from P0 to P15, before a slight reduction between P15 and P20 (Fig. 7B) .
Endogenous Dnmt expression in adult mouse brain
The levels of Dnmts were examined in different regions of the adult mouse brain. Dnmt1 protein levels were similar across many adult brain regions (Fig. 7C) . In contrast, levels for Dnmt3a showed brain-regional differences. Dnmt3a protein level was lowest in olfactory bulb and about threefold higher in diencephalon and brainstem (Fig. 7C) . Cerebral cortex, hippocampus, striatum, and cerebellum had comparable intermediate levels of Dnmt3a protein (Fig. 7C) .
Endogenous Dnmt expression in adult brain and spinal cord subcellular fractions
Because cell culture transfection experiments demonstrated targeting of Dnmt3a to mitochondria (Fig. 3B-E) , we examined brain and spinal cord subcellular fractions for Dnmt1 and Dnmt3a expression. Brain and spinal cord from C57/BL6 mice were fractionated in nuclear-enriched (P1), cytosol (S1), and pure mitochondria. The nuclear-enriched fraction of brain and spinal cord contained high levels of NeuN, whereas NeuN was not detected in the mitochondrial fractions (Fig.  7D) . The mitochondrial fraction of brain and spinal cord contained high levels of complex V, whereas complex V was not detected in the nuclear fraction (Fig. 7D) . Dnmt1 was present in the nuclear and cytosolic fractions in the brain and spinal cord (Fig. 7D) ; however, it was undetectable in the mitochondrial fraction (Fig.  7D) . Dnmt3a was present in not only the nuclear and cytosolic fractions but also in the pure mitochondrial fractions of both the brain and spinal cord (Fig. 7D) . Compared with Dnmt1, Dnmt3a levels were 3.62-and 3.66-fold higher in the brain nuclear and cytosolic fractions and 2.14-and 2.5-fold higher in the spinal cord, respectively (Fig. 7D) .
Endogenous Dnmts are upregulated during apoptosis of motor neurons in vivo
To examine the potential pro-apoptotic role of Dnmts in adult mouse spinal cord, we used a model of SNA that induces robust apoptosis of spinal motor neurons (Martin and Liu, 2002; Martin et al., 2005) . Unilateral lesions were made, and lumbar spinal cord microsamples were assayed for Dnmt protein and enzyme activity. By Western blotting, Dnmt1 levels were unchanged at 3 d after lesion but were elevated in both ipsilateral and contralateral sides at 4 and 5 d after lesion (Fig. 8A) . In contrast, Dnmt3a was markedly elevated (fourfold) on the lesioned side at 3 d (Fig. 8 A) . At 4 d, the ipsilateral Dnmt3a elevation was less prominent. At 5 d, Dnmt3a levels were similar in ipislateral and contralateral sides (Fig. 8 A) . Biochemical assay for total Dnmt enzyme activity revealed significant increases ipsilaterally at 3, 4, and 5 d (Fig. 8 B) .
Immunohistochemistry was used to study the cellular localizations of Dnmts in lumbar spinal cord motor neurons after SNA. At 5-14 d after lesion, Dnmt1 immunoreactivity was present ipsilaterally in numerous small ramified cells resembling microglia (Fig. 8C, hatched arrows) and in subsets of motor neurons (Fig. 8C, open arrow) , whereas, contralaterally, Dnmt1 was seen diffusely in the neuropil but was generally unapparent in motor neurons (Fig. 8 D) . Ipsilaterally, Dnmt1 was found enriched in the nucleus and cytoplasm of motor neurons with chromatin condensation suggestive of apoptosis (Fig. 8C, inset) . Dnmt3a was present in contralateral motor neurons (Fig. 8 E, open arrows) , where it was seen as discrete particles in the cytoplasm (Fig. 8G, hatched arrows) , faint and particulate nuclear matrix labeling (Fig. 8G, asterisk) , and as bouton-like structures near the plasma membrane (Fig. 8G, open arrows) . Subsets of ipsilateral motor neurons (Fig. 8 F, open arrows) showed a robust presence of Dnmt3a immunoreactivity in the nucleus (Fig.  8 H, asterisks) . To confirm that the Dnmt changes were occurring in spinal motor neurons rather than other spinal neurons that can be large or in nonneuronal cells, SNA lesions were done on adult transgenic mice expressing EGFP driven by the Hb9 promoter (Wichterle et al., 2002) , which have EGFP expressed in subsets of motor neurons at high levels (Chang and Martin, 2011; Martin, 2011) . Immunofluorescence for Dnmt1 confirmed the upregulation in the cytoplasm and nucleus of ipsilateral EGFP-positive motor neurons (Fig. 9A ) compared with contralateral motor neurons after SNA. Similarly, immunofluorescence for Dnmt3A suggested upregulation of Dnmt3A in the cytoplasm and nucleus of ipsilateral EGFP-positive motor neurons (Fig. 9B , open arrow and hatched arrow) compared to contralateral motor neurons after SNA. Moreover, Dnmt3A immunoreactivity was strongly upregulated in dendrites of ipsilateral motor neurons (Fig. 9B , double arrow).
Dnmt3a is localized to spinal cord synapses and mitochondria in vivo
Immunohistochemical assessments revealed that Dnmt3a might be located normally in some axosomatic synapses (Fig.  8G) . Immunofluorescence for Dnmt3a and the synaptic marker synpatophysin demonstrated that Dnmt3a is localized to synapses in mouse spinal cord (Fig. 8 J) . Many neurons were found to be decorated by perineuronal synapses positive for Dnmt3a (Fig. 8 J, open arrows) . Cell culture-transfection experiments (Fig. 3) and nervous tissue fractionation experiments (Fig. 7D) revealed that Dnmt3a is present in mitochondria. Immunofluorescence for Dnmt3a and the mitochondrial marker cyclophilin D (Martin et al., 2009b) demonstrated that Dnmt3a is localized to mitochondria in mouse spinal cord motor neurons (Fig. 8 I) .
DNA methylation is increased rapidly in motor neurons during apoptosis in vivo
Changes in Dnmts relate indirectly to DNA methylation. As a readout for DNA methylation directly in motor neurons during apoptosis, 5-mC was detected using an antibody. Antibody-based detection of 5-mC has been used before in studies of DNA methylation (Kang et al., 2006; Zhang et al., 2006) . In nonlesioned motor neurons, 5-mC immunoreactivity was observed as numerous small puncta within the cytoplasm and as delicate granules or strands in the nucleus (Fig. 10A) . In motor neurons destined to undergo apoptosis, obvious changes in the patterns of 5-mC were seen as early as 2 d after SNA (Fig. 10 B) , and increases in the levels of immunoreactivity were detected as soon as 3 d after injury (Fig. 10O) . The early-occurring changes in the patterns of 5-mC staining in Figure 7 . Developmentalexpression,regionaldistribution,andsubcellularlocalizationofDnmt1andDnmt3ainmouseCNS.A,Dnmt1 protein levels are very stable during normal postnatal development of mouse brain, whereas Dnmt3a levels increase. Mouse whole brains at P0 (day of birth) through P30 and into adulthood (8 weeks) were homogenized and used for immunoblotting for Dnmt1 and Dnmt3a. Membranes were stained with Ponceau S to show protein loading. Values in graphs are mean Ϯ SEM of optical density units. Asterisks denote a significant difference from P0 for Dnmt3a (p Ͻ 0.05). B, Dnmt1 protein levels decrease during postnatal development of mouse spinal cord, whereas Dnmt3a levels increase. Mouse whole spinal cords at P0 (day of birth) through P20 were homogenized and used for immunoblottingforDnmt1andDnmt3a.MembraneswerestainedwithPonceauStoshowproteinloading.ValuesingraphsaremeanϮ SEM of optical density units. Asterisks denote a significant reduction (p Ͻ 0.05) from P0 for Dnmt1 and a significant increase (p Ͻ 0.05) from P0 for Dnmt3a. C, Dnmt1 protein levels are uniform within different regions of adult mouse brain, whereas Dnmt3a levels show regional differences. Adult mouse brains were carefully microdissected into different regions that were homogenized and used for immunoblotting for Dnmt1 and Dnmt3a. Membranes were stained with Ponceau S to show protein loading. Values in graphs are mean Ϯ SEM of optical density units. D, Dnmt1 is found primarily in the nucleus and cytosol, whereas Dnmt3a is found in the nucleus, cytosol, and mitochondria. Adult mouse whole brains and whole spinal cords were homogenized; fractionated into nuclear (Nuc), cytosol (Cyto), and pure mitochondria (Mito) compartments; and used for immunoblotting for Dnmt1 and Dnmt3a. In both brain and spinal cord, the nuclear enrichment was confirmed by NeuN immunoreactivity, and mitochondrial enrichment was confirmed by mitochondrial complex V immunoreactivity.PonceauS-stainednitrocellulosemembranesshowproteinloading.ValuesingraphsaremeanϮSEMofopticaldensityunits. lesioned motor neurons included accumulation of particulate immunoreactivity in the cell body, proximal dendrites, and nucleus (Fig. 10 B) . To validate that these changes were indeed related to DNA modification, sections were treated with DNase or RNase before immunostaining with 5-mC antibody. DNase treatment completely abolished the 5-MeC immunoreactivity (Fig. 10C ), but digestion with RNase did not change the staining pattern (Fig. 10 D) . Evaluation of motor neurons in SNA mice at 5 d after lesion and thereafter revealed pronounced changes in 5-mC. As motor neurons underwent somatodendritic attrition, the entire nucleus became strongly positive for 5-mC and the cytoplasm showed numerous large 5-mC-positive aggregates (Fig. 10 E) . Progressive cellular attrition and loss of processes was associated with the presence of 5-mC-positive apoptotic body-like fragments in the neuropil (Fig. 10 F) . In advanced apoptotic attrition, the nucleus disintegrated into 5-mC-positive fragments (Fig. 10G) . Figure 7B for basal levels of Dnmt1 and Dnmt3a in mature (P20) whole mouse spinal cord. B, Dnmt enzyme activity in spinal cord increases ipsilaterally after SNA. Adult mice received unilateral SNA, and 3, 4, and 5 d later (n ϭ 4 per time), the lumbar spinal cords were microdissected into the nonlesioned contralateral control ventral horns (contra) and the lesioned ipsilateral ventral horns (ipsi). Crude homogenates were used for biochemical assessment of total Dnmt enzyme activity. Values in graphs are mean Ϯ SD. Asterisks denote a significant difference from contralateral at 3 and 4 d (p Ͻ 0.01) and at 5 d (p Ͻ 0.05). C, D, Immunohistochemical localization of Dnmt1 in mouse lumbar spinal cord at 4 d after SNA. Dnmt1 immunoreactivity was visualized with diaminobenzedine (brown), and sections were counterstained with cresyl violet. C, The ipsilateral ventral horn showed Dnmt1 immunoreactivity within the cytoplasm and nucleus of motor neurons (arrow and inset) and in small cells resembling microglia (hatched arrows). Some motor neurons with chromatin condensation typical of apoptosis (as seen by cresyl violet counterstaining) displayed aggregates of Dnmt1 immunoreactivity in the nucleus and perinuclear 4 region (inset; black circle delineates the nucleus). Scale bars: C (same for D), 20 m; C, inset, 10 m. D, In contrast, the contralateral ventral horn showed Dnmt1 immunoreactivity diffusely in the neuropil. E-H, Immunohistochemical localization of Dnmt3a in mouse lumbar spinal cord at 3 d after SNA as seen at low (E, F) and high (G, H) magnifications. Dnmt3a immunoreactivity was visualized with diaminobenzedine (brown), and sections were counterstained with cresyl violet. E, The contralateral control ventral horn showed Dnmt3a immunoreactivity within and around motor neurons (open arrows), but the nuclei of most motor neurons have low immunoreactivity in the nucleus. G, As seen at high resolution, Dnmt3a in normal motor neurons was seen faintly as diffuse immunoreactivity in the nucleus (asterisk) and in the cytoplasm as discrete puncta (hatched arrows). Pericellular bouton-like Dnmt3a immunoreactivity appeared in apposition to motor neurons (open arrows). F, H, In contrast, most ipsilateral motor neurons (F, open arrows) showed prominent Dnmt3a immunoreactivity in the nucleus (H, asterisks). Scale bars: in E (same for F), 20 m; in G (same for H, I), 5 m I, Confocal microscopy shows that some cytoplasmic Dnmt3a immunoreactivity in normal motor neurons is localized to mitochondria as demonstrated by its colocalization with the mitochondrial marker cyclophilin D (CyPD). Dnmt3a immunoreactivity is seen as green, and CyPD immunoreactivity is seen as red. Some cytoplasmic Dnmt3a immunoreactivity associates with mitochondria (seen as yellow), but single signals for Dnmt3a and CyPD can also be seen. Dnmt3a immunoreactivity is also seen in the nucleus (asterisk). J, Confocal microscopy shows that some Dnmt3a immunoreactivity is localized to presynaptic terminals as demonstrated by its colocalization with the presynaptic terminal marker synaptophysin. Dnmt3a immunoreactivity is seen as green, and synpatophysin (Synapto) immunoreactivity is seen as red. Perineuronal and peridendritic Dnmt3a is localized to axon terminals (hatched arrows, seen a yellow). Scale bar, 10 m.
5-mC immunoreactivity localizes to mitochondria
Because Dnmt3a can localize to mitochondria (Figs. 3, 8 I) and because DNA digestion eliminated the cytoplasmic punctate staining for 5-mC (Fig. 10C) , we examined whether some of the cytoplasmic structures positive for 5-mC were mitochondria, providing evidence for mitochondrial DNA methylation. An appreciable amount of the cytoplasmic punctate 5-mC immunoreactivity in motor neurons colocalized with the mitochondrial marker SOD2 (Fig. 10 H) . However, some of the larger aggregates of cytoplasmic 5-mC did not colocalize with SOD2 (Fig. 10 H) and have been shown to colocalize with an autophagosome marker (B. Gertz and L. J. Martin, unpublished observations).
Dnmt inhibition potently protects against apoptosis of motoneurons in vivo
Neuronal cell culture experiments showed that Dnmt inhibition and knockdown protect against apoptosis (Fig. 5) . To determine whether this finding translates to an in vivo setting, mice with SNA were treated repetitively with intracerebroventricular RG108. Treatment of SNA mice with RG108 nearly completely protected motor neurons against apoptosis (Fig. 10 I-K ) . The effect was sustained through 21 d after injury. In addition, RG108 fostered hypertrophy of injured motor neurons but not contralateral motor neurons, as evidence by the increased cell body volume (Fig. 10 L) . RG108 also profoundly blocked the postlesion increase in 5-mC immunoreactivity in motor neurons . Intraventricular RG108 had no overt untoward effects on mice.
Dnmt protein expression and 5-mC are upregulated in human ALS
Because our results in cell culture and mouse models indicate that DNA methylation can participate in the mechanisms of motor neuron degeneration, we examined whether these findings might be relevant to human sporadic ALS. As in wild-type mouse brain (Fig. 7D) , Dnmt1 was primarily confined to the nuclear fraction in extracts of control human motor cortex, but barely detectable Dnmt1 was also present in the mitochondrial fraction (Fig. 11A) . The nuclear fraction was enriched in NeuN (Fig. 11 A) . In human ALS motor cortex, Dnmt1 protein levels were increased in the Figure 9 . SNA lesions in transgenic mice expressing eGFP selectively in motor neurons. Hb9-eGFP transgenic mice confirm the expression of Dnmt1 (A) and Dnmt3a (B) in adult motor neurons and their upregulation in ipsilateral motor neurons after SNA compared with contralateral nonlesioned motor neurons, and they potentially serve as a reported model for DNA methylation silencing of gene expression during apoptosis. Motor neurons are labeled genetically with eGFP. Dnmt1 or Dnmt3a immunoreactivities are seen as red, and nuclear labeling is blue (Hoechst). Some ipsilateral lumbar motor neurons can be found with a high eGFP signal (A, B, open arrows), whereas in other motor neurons, the eGFP signal is attenuated or nearly abolished (A, B, hatched arrows). Motor neurons with greater Dnmt1 or Dnmt3a signal generally have a lower eGFP signal (hatched arrows). Dnmt1 immunoreactivity was also seen associated with small cells (A, double arrow). Dnmt3a immunoreactivity was also upregulated in dendrites of motor neurons (B, double arrow). Scale bars, 7 m. nuclear fraction (Fig. 11 B) , and Dnmt1 was also found in the mitochondrial fraction, which was also enriched in cyclophilin D (Fig. 11 A, B) . Dnmt3a in extracts of human control motor was highly en- sections did not alter the 5-mC immunoreactivity in motor neurons. E-G, Adult motor neurons at different morphological stages of the apoptotic process Martin and Liu, 2002) show marked changes in 5-mC immunoreactivity. E, In the chromatolytic stage, the nucleus becomes completely positive for 5-mC immunoreactivity (asterisk) and large aggregates of 5-mC accumulate in the cytoplasm. F, In the somatodendritic attrition stage, characterized by cell-body shrinkage and loss of processes, the nucleus remains strongly positive for 5-mC (asterisk), and 5-mC immunoreactive debris is found in the neuropil (arrow). G, At near end stage, characterized by a residual cell body without processes, the 5-mC immunoreactivity dissipates, and the nucleus is seen as fragments of 5-MeC immunoreactivity (asterisk). H, Confocal microscopyshowsthat some cytoplasmic 5-mC immunoreactivity in nonlesioned motor neurons is localized to mitochondria, as demonstrated by its colocalization with the mitochondrial marker SOD2. 5-mC immunoreactivity is seen as red, and SOD2 immunoreactivity is seen as green. Much of the cytoplasmic Dnmt3a immunoreactivity associates with mitochondria (seen as yellow), but single signals for 5-mC and SOD2 can also be seen. Scale bar, 10 m. I, J, Dnmt inhibitor RG108 completely blocks the degeneration of adult motor neurons after SNA. Mice were treated intracerebroventricularly with 10 g of RG108 (in 2 l of sterile saline) or with saline (vehicle) on day 0 (day of lesion) and on every other postlesion day over 3 weeks and were killed at 21 d after SNA. I, Vehicle-treated mice show loss of motor neurons in the ventral horn ipsilateral to the lesion. J, RG108-treated mice show no loss of motor neurons after SNA. Circles delineate lateral ventral horn regions. Scale bar, 120 m. K, Graph showing motor neuron cell counts in SNA mice treated with vehicle (saline) or RG108 and that survived for 21 d. Values (mean Ϯ SD) are represented as percentage of the ipsilateral motor neuron number relative to the contralateral nonlesioned side. The asterisk denotes significant difference ( p Ͻ 0.01) compared with vehicle. L, Graph showing motor neuron cell volumes in SNA mice treated with vehicle (saline) or RG108 and that survived for 21 d. Values (mean Ϯ SD) are represented as percentage of the remaining ipsilateral motor neuron volumes relative to the motor neuron volumes in the contralateral nonlesioned side. The asterisk denotes significant difference ( p Ͻ 0.01) compared with vehicle. M, N, Dnmt inhibitor RG108 completely blocks the rise in DNA methylation in adult motor neurons after SNA. Mice were treated intracerebroventricularly with 10 g of RG108 (in 2 l of sterile saline) or with saline (vehicle) on day 0 (day of lesion) and days 2 and 4 and were killed at 4 d after SNA. Ipsilateral lumbar motor neurons in vehicle mice displayed an increase in 5-MeC immunoreactivity in the nucleus and cytoplasm (M), and this rise in 5-mC immunoreactivity was blocked by RG108 (N). Scale bar, 7 m. O, Graph showing motor neuron 5-mC immunoreactivity in SNA mice treated with vehicle (saline) or RG108 and that survived for 3, 4 or 7 d. Quantification was done by single-cell densitometry (Martin et al., 2005) . Values (mean Ϯ SD) are the levels of 5-mC immunoreactivity in ipsilateral motor neurons as a percentage of the levels of 5-mC immunoreactivity in contralateral motor neurons. Asterisks denote significant differences at 3, 4, and 7 d ( p Ͻ 0.05, p Ͻ 0.01, and p Ͻ 0.001, respectively) compared with vehicle. Plus signs denotes significant differences at 4 and 7 d (p Ͻ 0.01, and p Ͻ 0.001, respectively) compared with 3 d vehicle. riched in nuclear and mitochondrial fractions, but low in the soluble fraction (Fig. 11 A) , in contrast to mouse brain where Dnmt3a was also enriched in the soluble fraction (Fig. 7D) . In human ALS motor cortex, Dnmt3a protein levels were increased in nuclear, soluble, and mitochondrial fractions (Fig. 11 A, B) .
Immunohistochemistry was used to determine the cellular localizations of Dnmt1, Dnmt3a, and 5-mC in control and ALS brain and spinal cord. In control human motor cortex, Dnmt1 was difficult to detect in neurons (Fig. 11C) , consistent with the low levels seen by immunoblotting (Fig. 11 A) , whereas small non-neuronal cells were occasionally positive (Fig. 11C, inset) . In ALS motor cortex, Dnmt1-positive neurons were easily identified (Fig. 11 D) , and Dnmt1 immunoreactivity was found accumulated in the nucleus of cortical neurons (Fig. 11 D, inset) . Dnmt3A in control motor cortex was seen faintly in the cytoplasm of subsets of neurons (Fig. 11 E) , in the neuropil (Fig. 11 E,  inset) , and in non-neuronal cells (Fig. 11 E, inset) . In ALS motor cortex, Dnmt3A-positive neurons were numerous (Fig. 11 F) . In control human motor cortex, 5-mC immunoreactivity was conspicuously low in pyramidal neurons, but the nuclei of apparent glial cells were stained intensely (Fig. 11G ). In contrast, pyramidal neurons in ALS motor cortex displayed strong 5-mC immunoreactivity, whereas nearby glial cells showed scant immunoreactivity (Fig. 11 H) . In control human spinal motor neurons, low Dnmt1 immunoreactivity was detected in the nucleus (Fig. 12 A, inset, asterisk) , whereas obvious Dnmt1 accumulations were found peripherally displaced in the cytoplasm (Fig.  12 , inset, open arrow). Many remaining attritional spinal motor neurons in ALS cases showed strong immunoreactivity for Dnmt1 in the nucleus and in perinuclear punctuate structures in the cytoplasm (Fig. 12 B, hatched arrows) . Dnmt3a immunoreactivity in human control motor neurons was localized in the cytoplasm where it appeared as numerous discrete puncta (Fig.  12C) and was also present as delicate beaded strands in the nuclear matrix and decorated the surface of the nucleolus (Fig. 12C , inset, hatched arrow). As in adult mouse spinal cord (Fig. 8 J) , Dnmt3a immunoreactivity was also seen as bouton-like structures in the neuropil of human spinal cord (Fig. 12C , inset, open arrows). In ALS cases, Dnmt3a immunoreactivity was found enriched in the perinuclear cytoplasm and accumulated in the nucleus of most remaining motor neurons (Fig. 12 D) . In control spinal cord, 5-mC immunoreactivity was present conspicuously in the nucleus of motor neurons and seen as a reticulum consistent with a chromatin pattern (Fig. 12 E) . In ALS motor neurons, the entire nucleus was immunoreactive for 5-mC, and many very attritional cells were completely immunoreactive (Fig. 12 F, inset) .
Discussion
This study was conducted to test the hypothesis that the mechanisms used to regulate DNA methylation in neurons can be used as mechanisms of neurodegeneration. We used a combination of cell culture and animal experimental designs to show that Dnmt activity can drive neuronal apoptosis. Dnmt3a has a particularly prominent pro-apoptotic function in motor neurons. Other new findings in this work include the identification of Dnmt3a in presynaptic axon terminals and its presence in mitochondria, as well as the presence of 5-mC in mitochondria, suggesting methylation of the mitochondrial genome by Dnmt3a. We also found upregulation of Dnmts and 5-mC in human ALS, suggesting that aberrant regulation of DNA methylation is part of the pathobiology of ALS.
We show for the first time that enforced function of Dnmts can drive neuronal apoptosis. In cultured spinal cord neurons, overexpression of Dnmt3a, but not Dnmt1, induced degeneration; furthermore, robust upregulation of Dnmt1 and Dnmt3a was antecedent to neuronal apoptosis induced by DNA damage. Mutation of the catalytically active site of Dnmt3a rendered it incompetent in inducing neurodegeneration, and inhibition of Dnmts with RG108 and procainamide and Dnmt RNAi protected cultured neurons from apoptosis. The finding that procainamide, a Dnmt1-specific inhibitor (Lee et al., 2005) , afforded much less neuroprotection than the more general inhibitor RG108 (Brueckner et al., 2005 ) supports our conclusion that Dnmt3a has stronger pro-apoptotic actions than Dnmt1 in neurons. The work was extended to an animal model of neurodegeneration where we showed several biochemical and pharmacological end points indicative of a postlesion Dnmt gain of function in mediating neuronal apoptosis.
Only three previous studies have suggested connections between Dnmt and neurodegeneration in brain or spinal cord injury models. Two studies have shown that Dnmt1 haploinsufficiency reduces infarct volume in adult mice (Endres et al., 2000 (Endres et al., , 2001 . However, it is difficult to interpret this neuroprotection vis-à-vis cell death, as stroke models are confounded by a highly heterogeneous, asynchronous neuropathology and coactivation of several different cell death signaling pathways, including apoptosis, necrosis, and autophagy (Martin et al., 1998 Puyal et al., 2009; Northington et al., 2011) . The other study used a bilateral dorsal column transection and sciatic nerve transection paradigm in rat or mouse to show that axon degeneration is paralleled by reduced Dnmt3a levels and genome hypomethylation in whole spinal cord (Iskandar et al., 2010) . However, relationships between epigenetic-related changes and neuronal cell death are also unclear in this model.
To study the possible role of Dnmts in neuronal apoptosis specifically within the CNS, divorced from other forms of cell death, we used an animal model featuring homogeneous and synchronous cellular pathology in a discrete CNS region. SNA induces selective retrograde neuronal degeneration in the spinal cord . The motor neurons die by a morphological process that is unequivocal apoptosis and requires the presence of the bax and p53 genes (Martin and Liu, 2002; Martin et al., 2005) . In this model, we showed that motor neuron apoptosis was associated with transient upregulation of Dnmt enzyme activity and Dnmt3a protein, subcellular changes in the localizations of Dnmt1 and Dnmt3a, and increased 5-mC in motor neurons. Importantly, treatment of mice with RG108 completely blocked the injury-induced enhancement of DNA methylation and the apoptosis of motor neurons. Previous studies of epigenetic regulation of neurodegeneration have focused primarily on histone acetylation (Sleiman et al., 2009 ); our study extends the concept of epigenetic mechanisms in the regulation of neuronal cell death by demonstrating a role for DNA methylation. methylation is a facet of the chromatin remodeling process preceding DNA cleavage.
It is interesting that nervous tissue mitochondria contain Dnmt. We found Dnmt3a in mitochondrial fractions of mouse and human CNS; in addition, Dnmt1 was found at low levels in human brain mitochondria. Recently, a mitochondrial targeting sequence was identified in Dnmt1, and it has been shown that Dnmt1, but not Dnmt3a, can localize to mitochondria in cultured mouse embryonic fibroblasts and human colon carcinoma cells (Shock et al., 2011) . The discrepancy here may be caused by the types of cells/tissues analyzed, because we have found the mitochondrial localization of Dnmt3a is tissue specific (Gertz and Martin, unpublished observations).
The involvement of Dnmts and DNA methylation in neuronal cell death could be relevant to human neurodegenerative disorders. Spinal muscular atrophy (SMA) and ALS are motor neuron diseases. SMA, occurring in 1 in 10,000 live births, is caused by mutations in the Survival of Motor Neuron (Smn) gene (Lefebvre et al., 1995) . A centromeric human-specific Smn2 gene is intact in a variable number of copies, but it fails to generate sufficient amounts of full-length SMN; however, the greater the SMN2 copy number, the milder the form of SMA. Interestingly, Smn2 gene silencing by DNA methylation correlates with SMA disease severity (Hauke et al., 2009) . In contrast to SMA, ALS is a fatal adult-onset disease, and the majority of ALS cases are sporadic with no known inherited component. Epidemiological studies implicate some environmental and acquired factors in its pathogenesis; however, previous genetic studies have been unable to uncover the genes involved in elucidating the molecular mechanisms of sporadic ALS. DNA methylation in sporadic ALS has been examined previously in two candidate genes, SOD1 and VEGF (Oates and Pamphlett, 2007) ; in members of the metallothione gene family (Morahan et al., 2007) ; and in the astroglial EAAT2 gene promoter (Yang et al., 2010) . None of these studies found differences in methylation patterns in sporadic ALS cases compared with control cases. Another study using genome-wide analysis of brain DNA methylation in sporadic ALS, accomplished by chromatin immunoprecipitation followed by CpG microarray hybridization, revealed significant hypermethylation of genes involved in calcium dynamics, oxidative stress, and synapses (Morahan et al., 2009) . We show in human sporadic ALS that Dnmt1 and Dnmt3a proteins are upregulated in motor cortex and spinal cord motor neurons and that immunoreactivity for 5-mC is increased in motor cortical pyramidal neurons. Moreover, our previous work reveals that motor neurons in human ALS degenerate with biochemical and morphological features resembling a variant form of apoptosis (Martin, 2010) . Our study thus supports the possibility that disease mechanisms involving aberrant DNA methylation could be relevant to human ALS pathobiology and therapeutic targeting.
